Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Operating Expenses (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Operating Expenses for 8 consecutive years, with $77.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Expenses rose 16.18% year-over-year to $77.3 million, compared with a TTM value of $318.4 million through Sep 2025, up 36.43%, and an annual FY2024 reading of $245.1 million, up 13.01% over the prior year.
  • Operating Expenses was $77.3 million for Q3 2025 at Bicycle Therapeutics, down from $89.5 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $89.5 million in Q2 2025 and bottomed at $17.8 million in Q1 2021.
  • Average Operating Expenses over 5 years is $48.3 million, with a median of $51.2 million recorded in 2024.
  • The sharpest move saw Operating Expenses soared 76.08% in 2022, then grew 2.75% in 2024.
  • Year by year, Operating Expenses stood at $21.8 million in 2021, then skyrocketed by 62.4% to $35.4 million in 2022, then skyrocketed by 68.28% to $59.6 million in 2023, then grew by 19.82% to $71.4 million in 2024, then grew by 8.29% to $77.3 million in 2025.
  • Business Quant data shows Operating Expenses for BCYC at $77.3 million in Q3 2025, $89.5 million in Q2 2025, and $80.2 million in Q1 2025.